Acadian Asset Management
PYXS icon

Acadian Asset Management’s Pyxis Oncology PYXS Stock Holding History

Acadian Asset Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Sell
126,793
-17,463
-12% -$33.4K ﹤0.01% 1513
2026
Q1 		$209K Buy
+144,256
New +$217K ﹤0.01% 1570
2025
Q4 		– Sell
-43,082
Closed -$94K – 2090
2025
Q3 		$94K Buy
43,082
+24,140
+127% +$34.8K ﹤0.01% 1535
2025
Q2 		$20K Sell
18,942
-65,180
-77% -$73.4K ﹤0.01% 1588
2025
Q1 		$81K Buy
+84,122
New +$112K ﹤0.01% 1378
2024
Q1 		– Sell
-11,278
Closed -$20K – 1742
2023
Q4 		$20K Sell
11,278
-1,955
-15% -$3.35K ﹤0.01% 1589
2023
Q3 		$26K Buy
+13,233
New +$30.7K ﹤0.01% 1506
2023
Q2 		– Sell
-32,506
Closed -$130K – 1873
2023
Q1 		$130K Sell
32,506
-39,196
-55% -$78.3K ﹤0.01% 1342
2022
Q4 		$95K Buy
71,702
+47,859
+201% +$71.8K ﹤0.01% 1450
2022
Q3 		$46K Hold
23,843
– – ﹤0.01% 1506
2022
Q2 		$57K Buy
+23,843
New +$63.5K ﹤0.01% 1475

Other funds holding PYXS

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management's PYXS Position: Q2 2026 in Review

Acadian Asset Management reduced its Pyxis Oncology (PYXS) stake by 12% in Q2 2026, selling an estimated $33.4K and leaving 126,793 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

Acadian Asset Management first reported a position in PYXS in Q2 2022 and has held it in 11 quarters since. 50 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Acadian Asset Management held 126,793 shares of Pyxis Oncology worth $380K as of Q2 2026.
  • Acadian Asset Management sold 17,463 Pyxis Oncology shares in Q2 2026, an estimated $33.4K.
  • Pyxis Oncology made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1513 holding.
  • Acadian Asset Management first reported a position in Pyxis Oncology in Q2 2022 and has held it in 11 quarters since.
  • 50 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.